Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding AgentMOLECULAR CANCER THERAPEUTICSIF5.52021-07-2619OAAI
Modulation of lymphocyte-mediated tissue repair by rational design of heterocyclic aryl hydrocarbon receptor agonistsSCIENCE ADVANCESIF12.52020-01-1741OAAI
Developing a novel FRET assay, targeting the binding between Antizyme-AZINSCIENTIFIC REPORTSIF3.92019-03-156OAAI
Antizyme inhibitor editing modulates nuclear localization but not antizyme binding: Implications for prostate cancerCANCER RESEARCHIF16.62018-07-010PRE
Synthesis and anticancer activity of novel water soluble benzimidazole carbamatesEUROPEAN JOURNAL OF MEDICINAL CHEMISTRYIF5.92018-01-0191PREAI
In silico discovery and therapeutic potential of IDO1 and TDO2 inhibitorsFUTURE MEDICINAL CHEMISTRYIF3.42017-08-033PREAI
Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyaseEUROPEAN JOURNAL OF MEDICINAL CHEMISTRYIF5.92017-01-0168PREAI
Multicolor Monitoring of the Proteasome's Catalytic SignatureACS CHEMICAL BIOLOGYIF3.82014-11-076OAAI
The indolyl-chalcone CDD-026 induces cancer cell death through targeting of STMN1 and mitotic catastropheEUROPEAN JOURNAL OF CANCERIF7.12014-11-010PREAI
Long-Wavelength Fluorescent Reporters for Monitoring Protein Kinase ActivityANGEWANDTE CHEMIE-INTERNATIONAL EDITIONIF16.92014-03-0627OAAI
A broad spectrum dark quencher: construction of multiple colour protease and photolytic sensorsCHEMICAL COMMUNICATIONSIF4.22013-01-0111OA
Suborganelle Sensing of Mitochondrial cAMP-Dependent Protein Kinase ActivityJOURNAL OF THE AMERICAN CHEMICAL SOCIETYIF15.62010-04-0974OAAI